Internet resources
Searching the Internet for new information can be useful and rewarding. The following sites can serve as convenient starting points. Many of them are updated frequently and have information covering a wide range of issues.
National Institutes of Health Clinical Trials Resource
For information regarding ongoing clinical trials for TYKERB, search “breast cancer, lapatinib.”
American Cancer Society
1.800.227.2345
Comprehensive Web site with information for cancer patients, families, friends, survivors, professionals, and volunteers.
breastcancer.org
Web site dedicated to educational information on breast cancer. Offers live, online "Ask the Expert" chat sessions (prior transcripts are archived and available on the Web site).
Breast CancerTM Network of Strength
1.800.221.2141 (24-hour hotline)
1.800.986.9505 (24-hour hotline in Spanish)
Information about breast cancer diagnosis, national advocacy and support groups, general information on clinical trials, and a 24-hour hotline.
CancerCare®
1.800.813.HOPE (1.800.813.4673)
Offers free, professional help through counseling, education, referrals, and financial assistance.
Cancer Information ServiceTM (National Cancer Institute)
1.800.4.CANCER (1.800.422.6237)
National information network with links to several other Internet resources, including educational materials, news, clinical trials, etc.
HER2 Support Group
A site designed by and for those with HER2-positive breast cancer. Find resources, news, and a community of professionals, volunteers, and fellow survivors.
HER Move
HER Move is a dynamic and empowering health and wellness program creating a movement that speaks directly to the unique challenges of living with HER2-positive breast cancer.
Living Beyond Breast Cancer
1.888.753.5222
Assists women at all stages of diagnosis, treatment, and recovery through specialized programs and services for the newly diagnosed, young women, women with advanced breast cancer, women at high risk for developing the disease, African-American and Latina women, and caregivers.
National Breast Cancer Coalition
1.800.622.2838
An organization dedicated to ending breast cancer by lobbying for public policies that impact breast cancer research, diagnosis, and treatment.
Sisters Network
1.866.781.1808
An organization committed to increasing local and national attention to the devastating impact that breast cancer has in the African-American community.
Susan G. Komen for The Cure
1.800 IM AWARE® (1.800.462.9273)
A grassroots network of survivors and activists fighting to save lives, empower people, ensure quality of care for all, and energize science to find the cures.
The Wellness Community®
1.888.793.WELL (1.888.793.9355)
Offers professionally led support groups, educational workshops, and mind/body programs to help patients regain a sense of control and restore hope.
Young Survival Coalition®
1.646.257.3000
Information and resources for young women affected by breast cancer.
Note: GlaxoSmithKline cannot take responsibility for information found on third-party Web sites outside its control. Please understand that the content of these third-party Web sites is subject to change without notice to GlaxoSmithKline. We therefore cannot be responsible for, and accept no liability for, any information or opinion contained in any third-party Web site.
Ask the Experts
Get answers to your questions about TYKERB.
Get More Information
Get updates from www.TYKERB.com.
Get support from Tykerb® CARES
Indication
TYKERB is indicated in combination with Xeloda® (capecitabine) for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and Herceptin® (trastuzumab).
Important Safety Information
Some women may develop liver damage while taking TYKERB. The cause of this damage is not known. In some cases, liver damage may be severe and may cause death. Your doctor should test your liver before and during treatment with TYKERB to check for signs of liver damage. You should contact your doctor if you have itching, yellow eyes or skin, dark urine, pain in your right upper side of your belly or feel very tired. If you develop liver damage during your treatment, your doctor may tell you to stop taking TYKERB. Before taking TYKERB, tell your doctor if you have liver problems. You may need a lower dose of TYKERB.
Before taking TYKERB, tell your doctor if you have heart problems. As with other treatments for HER2-positive advanced or metastatic breast cancer, there have been reports of changes in how the heart pumps blood through the body and how the heart beats. Call your doctor right away if you are short of breath, have rapid heartbeats (palpitations), or feel very tired.
Some people taking TYKERB have reported diarrhea. In some cases, diarrhea can be severe. Call your doctor right away if you have diarrhea. It is important to manage diarrhea with medicine as soon as it begins. Severe diarrhea may need to be treated with electrolytes and fluids given by mouth or by vein. Treatment with TYKERB may have to be delayed for a while or stopped completely.
If you have a dry cough or have shortness of breath, talk with your doctor. These may be signs of inflammation in the lungs.
Women should not become pregnant when taking TYKERB because the unborn baby may be harmed.
The most common side effects reported by patients taking TYKERB and Xeloda were diarrhea; vomiting; feeling sick to your stomach (nausea); feeling tired; red, painful hands and feet; and rash.
Tell your doctor about all the medicines you take, including prescription and nonprescription medicines and herbal and dietary supplements.
Because TYKERB is currently indicated to be taken with another medicine called Xeloda, be sure to talk with your doctor about any medicines and supplements that should be avoided when taking Xeloda.
Please see complete US Prescribing Information for TYKERB.
Xeloda is a registered trademark of Roche Laboratories Inc.
Herceptin is a registered trademark of Genentech, Inc.
Photos are for illustrative purposes only.
This website is funded and developed by GlaxoSmithKline.
This site is intended for US residents only.
© 1997-2010 GlaxoSmithKline. All Rights Reserved.
Legal Notices | Privacy Statement | Contact Us